Health Condition 1: N00-N99- Diseases of the genitourinary system
Conditions
Interventions
Intervention1: Sailani and Marham Dakhliyun Murakkab: 2 tablet BD for 14 days and 5 gm intravaginally, LA for 14 days respectively
Control Intervention1: Tab. Metronidazole 400 mg, TDS by oral route f
Sponsors
Department of Amrazeniswan wa Atfal
Eligibility
Inclusion criteria
Inclusion criteria: Patients in the age group of 18- 45 yrs. Patients complaining of vaginal discharge, pruritus, dysuria, and frequency of micturition. Presence of Clue cells in Microscopic examination. Patients willing to take part in study.
Exclusion criteria
Exclusion criteria: Unmarried women, pregnant women, and lactating mothers. Patients on oral contraceptive or using intrauterine contraceptive device and a history of taking antibiotic therapy from last 2 weeks. Patients with any systemic illness like anemia, TB, diabetes mellitus and sexually transmitted diseases. The patients suffering from candidiasis, trichomoniasis, chlamydial vaginitis, diphtheritic vaginitis, granular vaginitis, senile vaginitis, emphysematous vaginitis, vaginitis adhaesiva, neoplasm of cervix or vagina extensive chronic cervicitis, fibroid, and malignancy or any other systemic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy will be assessed by relief of clinical signs and symptoms such as vaginal discharge, pruritus, dysuria and frequency of micturition.And presence of clue cells in microscopic examination ( If present).With weekly follow up for 2 weeks.Timepoint: 2 weeks with weekly follow up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relief in vaginal discharge, malodour, low backache and lower abdomen pain along with negative amine(whiff) test and absence or reduction in the clue cells in saline wet mount examination with weekly follow up upto 2 weeks.Timepoint: 2 weeks with weekly follow up | — |
Countries
India
Contacts
Public ContactSadia Riaz
Department of Amraz-e-niswan wa Atfal
Outcome results
None listed